Decoding the Tumor-Immune Intersection: Opportunities for Breakthroughs in Cancer Therapies
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".
Deadline for manuscript submissions: 25 January 2026 | Viewed by 33
Special Issue Editor
Special Issue Information
Dear Colleagues,
As eye-catching headlines about cancer immunotherapy continue to emerge, transforming the landscape of cancer treatment, many advanced cancers remain incurable. Recent studies emphasize the need to investigate tumors as ecosystems composed of diverse cell types and states, highlighting therapeutic opportunities at the intersections between cancer cells and the immune system. Not long ago, cancer biology and immunology were considered separate fields. However, groundbreaking evidence now shows that oncogenic and oncometabolic pathways have a significant impact on the immune system and influence the effectiveness of immunotherapy. Conversely, immune cells also modulate cancer cell signaling and tumor responses to chemotherapy and targeted therapies. Therefore, integrating therapies that target the interface between cancer and immune cells is likely to overcome the limitations of current treatments focused on either type alone. This Special Issue of Cells will highlight the fundamental mechanisms of tumor-immune interactions and feature therapeutic strategies that could harness these interactions to enhance current cancer therapies. It will include a collection of original research articles, reviews, and communications.
Dr. Qiwei Wang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immuno-oncology
- tumor-immune interface
- tumor microenvironment
- cancer immunotherapy
- targeted therapy
- immunometabolism
- oncometabolism
- epigenetics
- combination strategies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
